Case Study: FIH Radiopharmaceutical Trial Across South Korea and US

A Phase 1 radiopharmaceutical program entered startup with protocol uncertainty, specialized vendor dependencies, and uneven site readiness. Progress required focused governance, capability-based activation, and constant adjustment across regions.

A first-in-human radiopharmaceutical study can look manageable on paper and become far more demanding once startup begins. That was the situation here. The study entered execution with a complex protocol, a sponsor that was still building experience in radiopharmaceutical development, and a delivery model that depended on specialized vendors, cross-border logistics, and sites willing to take on non-standard operational burden.

Early planning assumed broad indication coverage and a larger site footprint, but the real work quickly became narrower and more practical: identify what was truly executable, stabilize the parts of the program that were still moving, and keep progress going while the operating model matured.

Study Overview

The study’s complexity started with the science. In dose escalation, sites had to manage hospital stays, radioactive investigational product, hot sample handling, dedicated equipment, specialized procedures, and compliant shipment workflows. Those requirements created immediate friction during site engagement. Some sites were not fully equipped to take on that burden. Others had the baseline capability but were not willing to absorb another high-complexity study into an already demanding portfolio.

At the same time, the sponsor was still finding its footing in radiopharmaceutical development. The program was moving through protocol revisions during startup, and medical writing support had not been involved early enough. Vendor selection was also constrained by capability, not preference. The study needed an imaging structure that could support dosimetry, a laboratory vendor licensed to handle hot samples, and an importation pathway that could move radioactive investigational product from South Korea into the US.

Feasibility had to be reset around what the study could actually support

This created a startup environment where several foundational decisions were still evolving while execution had already begun. That is manageable only if governance is strong and the team stays disciplined about what needs to be solved first.

Strategic Focus for High-Complexity Radiopharmaceutical Program

One of the earliest course corrections was around scope. The program was initially considering six indications, with agency feedback prompting a reassessment of whether all of them were necessary. A narrower focus was under active consideration. That mattered operationally because early-phase radiopharmaceutical studies do not benefit from unnecessary breadth. They benefit from clarity, control, and tight execution.

In this kind of study, pace comes from activating the right sites, in the right sequence, with systems that can hold under pressure.

Protocol Quality Became a Central Operational Issue

The protocol itself became one of the biggest drivers of complexity. According to the study team, the original document needed significant work and was already moving toward change while startup activities were underway. A new medical lead recognized the gaps, and medical writing support was being brought in to help stabilize the design.

That matters because protocol quality in a radiopharmaceutical trial shapes every downstream decision: which sites are viable, what vendors are needed, how patients move through the schedule, what logistics are required, and where the burden falls during dose escalation. When that foundation is still shifting, every other workstream feels it.

Vendor Architecture was Defined by Capability

This study required a vendor ecosystem that could support radiopharmaceutical execution under real-world constraints. The team had to identify an importer of record with the right licenses to bring radioactive investigational product into the US. They also needed a lab vendor able to receive and process hot samples. That immediately narrowed the field.

Imaging introduced another layer. The study depended on an imaging partner working with a dosimetry provider that had become the practical standard for this type of work. That dependency created bottlenecks. The team experienced communication lapses, delayed deliverables, and inconsistent responsiveness, which led to escalation and direct performance management. Replacing the infrastructure was considered, but doing so would have introduced reset costs, duplicated work, and additional delay. The more pragmatic decision was to intensify oversight and stabilize execution within the existing model.

That is a familiar pattern in early-phase operations. Once a specialized vendor structure is in motion, the fastest path is often stronger governance rather than a midstream rebuild.

Global Coordination Added Another Layer of Friction

This was also a multi-region coordination challenge. The clinical operations team sat in North America, key stakeholders remained in South Korea, and parts of the delivery team operated across APAC and Europe. That introduced time zone strain, communication complexity, and cultural nuance that had to be managed actively.

The project director was pulled into sponsor-facing calls in part because regional roles were not yet functioning with the level of autonomy the study required. Some team members had the expertise but were not fully comfortable operating directly with the sponsor. That is not unusual in a new regional model, but it does create an extra coordination load at the leadership level. Maintaining continuity required more direct involvement than the original structure likely anticipated.

The broader point is global execution depends on role clarity, communication confidence, and an operating rhythm that works across functions and regions.

From Startup Friction to Executable Design

The study did not move forward because complexity disappeared. It moved forward because the team kept narrowing the problem into executable pieces. Site strategy became capability-based. Vendor management became more assertive. Importation and sample logistics were designed around regulatory reality. Protocol quality became a visible priority. Leadership stepped in where regional execution needed reinforcement.

That kind of progress is what real operational recovery looks like in a high-complexity trial. Programs like this move when teams keep the infrastructure aligned to what the study can actually support and resist the temptation to scale ahead of proof.

Several lessons stand out from this program:

1. Feasibility has to reflect operational burden: A site may be scientifically interested and still not be practically ready. In radiopharmaceutical studies, capability and tolerance for burden matter as much as enthusiasm.

2. Protocol quality has to be locked earlier: When medical writing and operational design come in too late, the consequences reach across startup, vendor planning, and site activation.

3. Specialized studies narrow vendor choice quickly: Importation, hot sample handling, imaging, and dosimetry requirements define the partner ecosystem. They need to be recognized early.

4. Governance is part of delivery: Escalation frameworks, close vendor oversight, and hands-on cross-functional alignment are primary parts of the work itself in a study like this.

5. International execution needs deliberate role design: Cross-border programs succeed when sponsor-facing ownership, regional expertise, and decision pathways are clear from the start.

Running Complex Radiopharmaceutical Trials

Complex radiopharmaceutical trials rarely break down at a single point. More often, they expose misalignment across design, infrastructure, site capability, and governance all at once. This study shows what it takes to keep moving in that environment: disciplined scope control, realistic activation strategy, focused vendor management, and leadership willing to stay close to the work until the model becomes more stable.

At Precision, this is the kind of execution challenge that benefits from operational experience early, before constraints begin to stack on top of each other. When studies require specialized infrastructure, regional coordination, and constant adjustment, building an operating model that can hold under real conditions comes first.